Long-term titrated recombinant interferon-alpha 2a in chronic hepatitis C

a randomized controlled trial.

M. G. Rumi, E. del Ninno, M. L. Parravicini, R. Romeo, R. Soffredini, M. F. Donato, F. Zahm, M. Colombo

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

The efficacy and tolerability of 12-month treatment with titrated doses of recombinant interferon-alpha 2a (IFN-alpha 2a) in chronic hepatitis C were studied in 67 consecutively recruited patients randomly assigned either to a starting dose of IFN-alpha 2a 6 MU, subsequently adjusted to the serum alanine aminotransferase (ALT) response (n = 35), or to no therapy (n = 32; controls). End-of-treatment ALT levels were normal and hepatitis C virus (HCV) RNA was negative by nested polymerase chain reaction (PCR) in 17 (49%) treated patients compared to none of the controls (P <0.001). During the 12 months after stopping treatment the number of patients who remained in remission was eight (23%) and one respectively (4%) (P = 0.031). Follow-up liver biopsy showed reduced hepatic inflammation in 80% of treated patients and in 29% of controls (P <0.001). The eight sustained responders and 27 non-responders or relapsers received similar mean total doses of IFN (565 MU vs 545 MU) and had a similar incidence of anti-IFN neutralizing antibodys (13% vs 19%). Absence of cirrhosis was the only independent pretreatment parameter that predicted a sustained response. In conclusion, a mean cumulative dose of IFN 549 MU, titrated over 12 months, was well tolerated, and resulted in the long-term clearance of HCV RNA and normal ALT levels in 23% of patients.

Original languageEnglish
Pages (from-to)73-76
Number of pages4
JournalJournal of Viral Hepatitis
Volume2
Issue number2
Publication statusPublished - 1995

Fingerprint

Chronic Hepatitis C
Randomized Controlled Trials
Alanine Transaminase
Hepacivirus
RNA
Liver
Therapeutics
Fibrosis
interferon alfa-2a
Inflammation
Biopsy
Polymerase Chain Reaction
Incidence
Serum

ASJC Scopus subject areas

  • Hepatology
  • Virology

Cite this

Long-term titrated recombinant interferon-alpha 2a in chronic hepatitis C : a randomized controlled trial. / Rumi, M. G.; del Ninno, E.; Parravicini, M. L.; Romeo, R.; Soffredini, R.; Donato, M. F.; Zahm, F.; Colombo, M.

In: Journal of Viral Hepatitis, Vol. 2, No. 2, 1995, p. 73-76.

Research output: Contribution to journalArticle

@article{fbbd2a33d6c546b293d908639a7980eb,
title = "Long-term titrated recombinant interferon-alpha 2a in chronic hepatitis C: a randomized controlled trial.",
abstract = "The efficacy and tolerability of 12-month treatment with titrated doses of recombinant interferon-alpha 2a (IFN-alpha 2a) in chronic hepatitis C were studied in 67 consecutively recruited patients randomly assigned either to a starting dose of IFN-alpha 2a 6 MU, subsequently adjusted to the serum alanine aminotransferase (ALT) response (n = 35), or to no therapy (n = 32; controls). End-of-treatment ALT levels were normal and hepatitis C virus (HCV) RNA was negative by nested polymerase chain reaction (PCR) in 17 (49{\%}) treated patients compared to none of the controls (P <0.001). During the 12 months after stopping treatment the number of patients who remained in remission was eight (23{\%}) and one respectively (4{\%}) (P = 0.031). Follow-up liver biopsy showed reduced hepatic inflammation in 80{\%} of treated patients and in 29{\%} of controls (P <0.001). The eight sustained responders and 27 non-responders or relapsers received similar mean total doses of IFN (565 MU vs 545 MU) and had a similar incidence of anti-IFN neutralizing antibodys (13{\%} vs 19{\%}). Absence of cirrhosis was the only independent pretreatment parameter that predicted a sustained response. In conclusion, a mean cumulative dose of IFN 549 MU, titrated over 12 months, was well tolerated, and resulted in the long-term clearance of HCV RNA and normal ALT levels in 23{\%} of patients.",
author = "Rumi, {M. G.} and {del Ninno}, E. and Parravicini, {M. L.} and R. Romeo and R. Soffredini and Donato, {M. F.} and F. Zahm and M. Colombo",
year = "1995",
language = "English",
volume = "2",
pages = "73--76",
journal = "Journal of Viral Hepatitis",
issn = "1352-0504",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "2",

}

TY - JOUR

T1 - Long-term titrated recombinant interferon-alpha 2a in chronic hepatitis C

T2 - a randomized controlled trial.

AU - Rumi, M. G.

AU - del Ninno, E.

AU - Parravicini, M. L.

AU - Romeo, R.

AU - Soffredini, R.

AU - Donato, M. F.

AU - Zahm, F.

AU - Colombo, M.

PY - 1995

Y1 - 1995

N2 - The efficacy and tolerability of 12-month treatment with titrated doses of recombinant interferon-alpha 2a (IFN-alpha 2a) in chronic hepatitis C were studied in 67 consecutively recruited patients randomly assigned either to a starting dose of IFN-alpha 2a 6 MU, subsequently adjusted to the serum alanine aminotransferase (ALT) response (n = 35), or to no therapy (n = 32; controls). End-of-treatment ALT levels were normal and hepatitis C virus (HCV) RNA was negative by nested polymerase chain reaction (PCR) in 17 (49%) treated patients compared to none of the controls (P <0.001). During the 12 months after stopping treatment the number of patients who remained in remission was eight (23%) and one respectively (4%) (P = 0.031). Follow-up liver biopsy showed reduced hepatic inflammation in 80% of treated patients and in 29% of controls (P <0.001). The eight sustained responders and 27 non-responders or relapsers received similar mean total doses of IFN (565 MU vs 545 MU) and had a similar incidence of anti-IFN neutralizing antibodys (13% vs 19%). Absence of cirrhosis was the only independent pretreatment parameter that predicted a sustained response. In conclusion, a mean cumulative dose of IFN 549 MU, titrated over 12 months, was well tolerated, and resulted in the long-term clearance of HCV RNA and normal ALT levels in 23% of patients.

AB - The efficacy and tolerability of 12-month treatment with titrated doses of recombinant interferon-alpha 2a (IFN-alpha 2a) in chronic hepatitis C were studied in 67 consecutively recruited patients randomly assigned either to a starting dose of IFN-alpha 2a 6 MU, subsequently adjusted to the serum alanine aminotransferase (ALT) response (n = 35), or to no therapy (n = 32; controls). End-of-treatment ALT levels were normal and hepatitis C virus (HCV) RNA was negative by nested polymerase chain reaction (PCR) in 17 (49%) treated patients compared to none of the controls (P <0.001). During the 12 months after stopping treatment the number of patients who remained in remission was eight (23%) and one respectively (4%) (P = 0.031). Follow-up liver biopsy showed reduced hepatic inflammation in 80% of treated patients and in 29% of controls (P <0.001). The eight sustained responders and 27 non-responders or relapsers received similar mean total doses of IFN (565 MU vs 545 MU) and had a similar incidence of anti-IFN neutralizing antibodys (13% vs 19%). Absence of cirrhosis was the only independent pretreatment parameter that predicted a sustained response. In conclusion, a mean cumulative dose of IFN 549 MU, titrated over 12 months, was well tolerated, and resulted in the long-term clearance of HCV RNA and normal ALT levels in 23% of patients.

UR - http://www.scopus.com/inward/record.url?scp=0029445062&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029445062&partnerID=8YFLogxK

M3 - Article

VL - 2

SP - 73

EP - 76

JO - Journal of Viral Hepatitis

JF - Journal of Viral Hepatitis

SN - 1352-0504

IS - 2

ER -